Cognitive enhancers provide some benefits in patients with moderate to severe Alzheimer's disease

Author：

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.27, Iss.4, 2011-04, pp. : 9-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer's Disease

By Cappell Jaclyn Herrmann Nathan Cornish Stephen Lanctôt Krista L.

CNS Drugs, Vol. 24, Iss. 11, 2010-11 ,pp. : 909-927

Adis International

Access to resources Recommend Favorite

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease

By Wimo A.

PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. : 327-340

Adis International

Access to resources Recommend Favorite

Galantamine shows sustained cognitive benefits in patients with Alzheimer's disease (AD)

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Pharmacological treatment in moderate-to-severe Alzheimer's disease

By Hsiung Ging-Yuek Robin Feldman Howard H

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2575-2582

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Memantine in Moderate to Severe Alzheimer's Disease†

By McKeage Kate

Drugs & Aging, Vol. 27, Iss. 2, 2010-02 ,pp. : 177-179

Adis International

Access to resources Recommend Favorite